Galanin decreases the activity of locus coeruleus neurons in vitro

doi:10.1016/0014-2999(89)90481-0

European Journal of Pharmacology

Volume 164, Issue 2, 19 May 1989, Pages 373-376

https://doi.org/10.1016/0014-2999(89)90481-0 Get rights and content

Abstract

A brain slice preparation was used to examine the effects of galanin on the spontaneous firing rate of locus coeruleus noradrenergic neurons. Galanin (10⁻⁹-10⁻⁷ M), added to the bath, inhibited the firing of 14 out of 19 neurons in a concentration-dependent manner. The observed effect was quite variable, ranging from 20 to 100% at 10⁻⁷ M. Experiments performed in low-Ca²⁺, high-Mg²⁺ medium also showed a significant inhibition by galanin (10⁻⁷ M) in three out of five neurons, which suggests that the peptide acts directly.

References (10)

R. Andrade et al.
Morphine tolerance and dependence in the locus coeruleus: single cell studies in brain slices
European J. Pharmacol.
(1983)
H.L. Haas et al.
A simple perfusion chamber for the study of nervous tissue slices in vitro
J. Neurosci. Meth.
(1979)
O. Nordström et al.
Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence
Neurosci. Lett.
(1987)
A. Rökaeus et al.
A galanin-like peptide in the central nervous system and intestine of the rat
Neurosci. Lett.
(1984)
G. Skofitsch et al.
Immunohistochemical mapping of galanin-like neurons in the rat central nervous system
Peptides
(1985)

There are more references available in the full text version of this article.

Cited by (144)

Heterogeneous organization of Locus coeruleus: An intrinsic mechanism for functional complexity
2023, Physiology and Behavior
Locus coeruleus (LC) is a small nucleus located deep in the brainstem that contains the majority of central noradrenergic neurons, which provide the primary source of noradrenaline (NA) throughout the entire central nervous system (CNS).The release of neurotransmitter NA is considered to modulate arousal, sensory processing, attention, aversive and adaptive stress responses as well as high-order cognitive function and memory, with the highly ramified axonal arborizations of LC-NA neurons sending wide projections to the targeted brain areas. For over 30 years, LC was thought to be a homogeneous nucleus in structure and function due to the widespread uniform release of NA by LC-NA neurons and simultaneous action in several CNS regions, such as the prefrontal cortex, hippocampus, cerebellum, and spinal cord. However, recent advances in neuroscience tools have revealed that LC is probably not so homogeneous as we previous thought and exhibits heterogeneity in various aspects. Accumulating studies have shown that the functional complexity of LC may be attributed to its heterogeneity in developmental origin, projection patterns, topography distribution, morphology and molecular organization, electrophysiological properties and sex differences. This review will highlight the heterogeneity of LC and its critical role in modulating diverse behavioral outcomes.
The gating pore blocker 1-(2,4-xylyl)guanidinium selectively inhibits pacemaking of midbrain dopaminergic neurons
2021, Neuropharmacology
Although several ionic mechanisms are known to control rate and regularity of the slow pacemaker in dopamine (DA) neurons, the core mechanism of pacing is controversial. Here we tested the hypothesis that pacemaking of SNc DA neurons is enabled by an unconventional conductance. We found that 1-(2,4-xylyl)guanidinium (XG), an established blocker of gating pore currents, selectively inhibits pacemaking of DA neurons. The compound inhibited all slow pacemaking DA neurons that were tested, both in the substantia nigra pars compacta, and in the ventral tegmental area. Interestingly, bursting behavior was not affected by XG. Furthermore, the drug did not affect fast pacemaking of GABAergic neurons from substantia nigra pars reticulata neurons or slow pacemaking of noradrenergic neurons. In DA neurons, current-clamp analysis revealed that XG did not appear to affect ion channels involved in the action potential. Its inhibitory effect persisted during blockade of all ion channels previously suggested to contribute to pacemaking. RNA sequencing and voltage-clamp recordings yielded no evidence for a gating pore current to underlie the conductance. However, we could isolate a small subthreshold XG-sensitive current, which was carried by both Na⁺ and Cl⁻ ions. Although the molecular target of XG remains to be defined, these observations represent a step towards understanding pacemaking in DA neurons.
Neuropeptide modulation of addiction: Focus on galanin
2020, Neuroscience and Biobehavioral Reviews
Citation Excerpt :
Increased nicotine binding on NA neurons in the LC in response to smoking induces this stimulation of NA release (Jackson et al., 2011; Khoshbouei et al., 2002a, 2002b). Thus, GAL may protect against withdrawal signs of nicotine dependence via its inhibitory effect on NA release in the LC (Pieribone et al., 1995; Seutin et al., 1989). In contrast to these findings, a study employing GAL-KO mice revealed a decreased sensitivity to the rewarding effects of nicotine, compared to WT controls (Neugebauer et al., 2011).
Addiction is a chronic, relapsing disorder characterised by the use of a substance or act to the point of compulsion. There are a number of medical treatments available for the intervention of these disorders, however, the effectiveness of current therapeutics is far from adequate. Neuropeptides are known to modulate addictive behaviours and may provide new therapeutic targets for the treatment of substance abuse. Accumulating evidence has suggested galanin as a potential important neuromodulator of addiction. Both human genetic studies and animal models have highlighted a role for this neuropeptide in affective disorders, as well as alcohol, nicotine, and opiate dependence. This review highlights the role of galanin and other primary neuropeptides implicated in modulating addiction to different drugs of abuse. Orexin, relaxin-3, corticotrophin-releasing factor, dynorphin and enkephalin, are also discussed given their involvement in mediating reward-seeking behaviour.
Are neuropeptides relevant for the mechanism of action of SSRIs?
2019, Neuropeptides
Selective serotonin reuptake inhibitors (SSRIs) are drugs of first choice in the therapy of moderate to severe depression and anxiety disorders. Their primary mechanism of action is via influence of the serotonergic (5-HT) system, but a growing amount of data provides evidence for other non-monoaminergic players in SSRI effects. It is assumed that neuropeptides, which play a role as neuromodulators in the CNS, are involved in their mechanism of action. In this review we focus on six neuropeptides: corticotropin-releasing factor – CRF, galanin – GAL, oxytocin – OT, vasopressin – AVP, neuropeptide Y – NPY, and orexins – OXs. First, information about their roles in depression and anxiety disorders are presented. Then, findings describing their interactions with the 5-HT system are summarized. These data provide background for analysis of the results of published preclinical and clinical studies related to SSRI effects on the neuropeptide systems. We also report findings showing how modulation of neuropeptide transmission influences behavioral and neurochemical effects of SSRIs. Finally, future research necessary for enriching our knowledge of SSRI mechanisms of action is proposed. Recognition of new molecular targets for antidepressants will have a significant effect on the development of novel therapeutic strategies for mood-related disorders.
Circuit mechanisms and computational models of REM sleep
2019, Neuroscience Research
Rapid eye movement (REM) sleep or paradoxical sleep is an elusive behavioral state. Since its discovery in the 1950s, our knowledge of the neuroanatomy, neurotransmitters and neuropeptides underlying REM sleep regulation has continually evolved in parallel with the development of novel technologies. Although the pons was initially discovered to be responsible for REM sleep, it has since been revealed that many components in the hypothalamus, midbrain, pons, and medulla also contribute to REM sleep. In this review, we first provide an up-to-date overview of REM sleep-regulating circuits in the brainstem and hypothalamus by summarizing experimental evidence from neuroanatomical, neurophysiological and gain- and loss-of-function studies. Second, because quantitative approaches are essential for understanding the complexity of REM sleep-regulating circuits and because mathematical models have provided valuable insights into the dynamics underlying REM sleep genesis and maintenance, we summarize computational studies of the sleep-wake cycle, with an emphasis on REM sleep regulation. Finally, we discuss outstanding issues for future studies.
The neuropeptides Galanin and Galanin(1–15) in depression-like behaviours
2017, Neuropeptides
Galanin is a 29 amino acid neuropeptide widely distributed in neurons within the central nervous system. Galanin exerts its biological activities through three different G protein-receptors and participates in a number of functions, including mood regulation. Not only Galanin but also Galanin N-terminal fragments like Galanin(1–15) are active at the central level. In this work, we review the latest findings in studies on Galanin and Galanin(1–15) in depression-related behaviours. Our focus is on animal models for depression, and we pay some attention to research data obtained in human studies. Since Serotonin (5-HT), especially through 5-HT1A, and Galanin receptors interact at both pre-and postsynaptic level, the development of drugs targeting potential GAL₁-GAL₂-5-HT1A heteroreceptor complexes linked to the raphe-hippocampal 5-HT neurons may represent new treatment strategies in depression.

View all citing articles on Scopus

View full text

Short communicationGalanin decreases the activity of locus coeruleus neurons in vitro

Abstract

European J. Pharmacol.

J. Neurosci. Meth.

Neurosci. Lett.

Neurosci. Lett.

Peptides

Short communication
Galanin decreases the activity of locus coeruleus neurons in vitro